C4 Therapeutics Inc. held its Annual Meeting of Stockholders on June 18, 2025. During the meeting, the stockholders elected Ronald Harold Wilfred Cooper, Donna Grogan, M.D., and Steven Hoerter as Class II directors. Additionally, the stockholders approved an increase in the number of authorized shares of common stock from 150,000,000 to 300,000,000. The selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was also ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.